-transparent.png){kind=logo}
The use of tamoxifen for breast cancer therapy is linked to an increased danger of developing endometrial neoplasias in postmenopausal patients receiving the drug. Understanding the molecular mechanisms of the tumorigenic activity of tamoxifen may be of great prognostic and therapeutic significance. Our study suggests that tamoxifen treatment and alterations of the K-ras proto-oncogene may occur as parallel events in carcinogenesis of the endometrium.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
M Varras, and
G Zachos, and
D Spandidos
May 1995,
The Australian & New Zealand journal of obstetrics & gynaecology,
M Varras, and
G Zachos, and
D Spandidos
August 1991,
Journal of chemotherapy (Florence, Italy),
M Varras, and
G Zachos, and
D Spandidos
October 1999,
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,
M Varras, and
G Zachos, and
D Spandidos
January 2002,
European journal of gynaecological oncology,
M Varras, and
G Zachos, and
D Spandidos
March 1993,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Varras, and
G Zachos, and
D Spandidos
March 1994,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
M Varras, and
G Zachos, and
D Spandidos
January 1998,
Radiation medicine,
M Varras, and
G Zachos, and
D Spandidos
July 2001,
Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
M Varras, and
G Zachos, and
D Spandidos
November 2020,
Journal of the Royal Society of Medicine,
M Varras, and
G Zachos, and
D Spandidos
January 2003,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
